

## **KDA GROUP COMPLETES ACQUISITION OF ALL ZRX DIGITAL PRESCRIBER PROPRIETARY RIGHTS FROM ZOOMMED**

**Thetford Mines, Quebec – July 28, 2023** – KDA Group Inc. (TSXV: KDA) (“**KDA**” or the “**Corporation**”) and ZoomMed Inc. (“**ZoomMed**”) are pleased to announce that KDA has completed today the previously announced acquisition, in its press release dated June 30, 2023, of all the proprietary rights in the ZRx Digital Prescriber (the “**ZRx Prescriber**”) held by ZoomMed, in consideration of 10,000,000 Class A Shares of KDA’s share capital (the “**Transaction**”).

Groupe Technologique KDA Inc. (“**Tech KDA**”), a wholly owned subsidiary of the Corporation, acquired in May 2021 the ownership rights to the ZRx Prescriber to develop, market and operate the ZRx Prescriber in the United States, Europe and the United Kingdom (the “**Initial Territory**”), in consideration for 20,000,000 Class A shares of KDA’s share capital. The Corporation expects to transfer its rights in the ZRx Prescriber acquired pursuant to the Transaction to Tech KDA, which will enable Tech KDA to significantly expand the Initial Territory for the operation of the ZRx Prescriber.

The ZRx Prescriber is an electronic prescriber computer and mobile software designed and developed by ZoomMed Médical Inc., a wholly owned subsidiary of ZoomMed, for use by healthcare providers who are authorized to prescribe medications and other treatments.

The Transaction is effective as of July 28, 2023, and subject to the final approval from the TSX Venture Exchange. KDA and ZoomMed are arm’s length parties and no finder’s fee is payable in connection with the Transaction. Full details of the Transaction and certain other matters are set out in ZoomMed’s management information circular dated June 23, 2023, a copy of which can be found under the profile of ZoomMed on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca).

### **ABOUT KDA GROUP**

KDA Group is a leader in technological innovations and specialized solutions in the pharmaceutical market. KDA is a corporation that offers quality products and has a respected expertise among the various stakeholders in the pharmaceutical and medical sectors. Its management team is guided by the vision to pursue leading the way in Canada and internationally. Additional information about the Corporation is available at [www.kdagroup.ca](http://www.kdagroup.ca) and on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca).

## **CAUTION REGARDING FORWARD-LOOKING STATEMENTS**

*This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.*

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.*

## **INFORMATION**

Marc Lemieux, Chief Executive Officer

514 622-7370

[info@groupekda.ca](mailto:info@groupekda.ca)